Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

BACKGROUND: Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RT...

Descripción completa

Detalles Bibliográficos
Autores principales: Coussy, F., El Botty, R., Lavigne, M., Gu, C., Fuhrmann, L., Briaux, A., de Koning, L., Dahmani, A., Montaudon, E., Morisset, L., Huguet, L., Sourd, L., Painsec, P., Chateau-Joubert, S., Larcher, T., Vacher, S., Melaabi, S., Salomon, A. Vincent, Marangoni, E., Bieche, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036180/
https://www.ncbi.nlm.nih.gov/pubmed/32087759
http://dx.doi.org/10.1186/s13045-020-0846-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036180/
https://www.ncbi.nlm.nih.gov/pubmed/32087759
http://dx.doi.org/10.1186/s13045-020-0846-y

Ejemplares similares